Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

A reduction in depression scores of -12.64 was observed in women treated with desvenlafaxine compared to -8.33 in those receiving placebo over 8 weeks.

• Desvenlafaxine treatment led to a significantly greater decrease in depression symptoms compared to placebo, with statistical separation evident as early as week 1.
• Both perimenopausal and postmenopausal women experienced significant improvements in depression scores with desvenlafaxine.
• The response rate for desvenlafaxine was 58.6%, with a remission rate of 38.2%, both significantly higher than the rates for placebo.
• Adverse events were reported in 85.2% of desvenlafaxine-treated patients compared to 75.2% of those on placebo.
• Discontinuation due to adverse events occurred in 7.4% of desvenlafaxine patients and 3.2% of placebo patients.

AI simplified